ProLynx

company

About

ProLynx technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$230K
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2009
Number Of Employee
1 - 10
Operating Status
Active

ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company's technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs.

ProLynx was founded in 2009 by Daniel V. Santi and Gary W. Ashley and is based in San Francisco, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
10
$2.26M
ProLynx has raised a total of $2.26M in funding over 2 rounds. Their latest funding was raised on Jul 1, 2020 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 1, 2020 Grant $230K 1 National Institutes of Health Detail
Nov 1, 2018 Grant $150K 1 National Institutes of Health Detail
Nov 1, 2016 Grant $250K 1 National Science Foundation Detail
Jun 1, 2015 Grant $141.69K 1 National Science Foundation Detail
Nov 1, 2014 Grant $742.77K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
10
2
ProLynx is funded by 2 investors. National Institutes of Health and National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
National Science Foundation Yes Grant